Eisai grabbed an early green light on Friday from U.S. regulators for thyroid cancer drug Lenvima, meaning the Japanese pharma can now get an earlier-than-expected start on trying to make its blockbuster dreams a reality. If all goes as planned, the new therapy will be raking in $1 billion a year by 2020, a company exec told The Wall Street Journal this week, and Eisai's hoping to score future nods in liver, kidney, lung and endometrial cancers to help it get there. More from FierceBiotech